daily oral glp-1 receptor agonist orforglipron for adults with obesity FDA approves Foundayo, an alternative to Wegovy and Ozempic Discover Orforglipron: A New Oral
Description
Prevalence of hypertension among type 2 diabetes mellitus patients in Ethiopia: a systematic review and meta-analysis
Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lillys brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management
10.1073/pnas.1201191109 [DOI] [PMC free article] [PubMed] [Google Scholar] Song C., Wang H
Clinical trials showed average weight gains of 1 to 4 kg with Tresiba use
GLP-1 inhibits food intake and promotes satiety in healthy individuals and those with obesity and diabetes [33]
doi: 10.1016/S2213-8587(17)30013-X 221 ArodaVRRosenstockJTerauchiYAltuntasYLalicNMMorales VillegasECet al
